OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.   

The Company believes that the listing of its common shares on the NASDAQ exchange provides shareholders sufficient liquidity and has concluded that the cost of maintaining the listing of its common shares on the SSE outweighs the benefits of continuing such listing. Therefore, the Company has decided to delist its common shares from the SSE. The estimated last day of trading of OXiGENE shares on the SSE will be June 30, 2010.   

"Consolidating our shares into one market is a natural reflection of our newly focused, cost-conscious operations," commented Peter Langecker, M.D., Ph.D., OXiGENE Chief Executive Officer. "We remain grateful for the long-standing support of our Swedish shareholders, and are pleased that with today's trading technology they can continue to participate in the company's success via the NASDAQ exchange."